Who are Placebo matching mepolizumab's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Asthma therapies, Fasenra®, EXDENSUR, Mepolizumab Injection [Nucala], Benralizumab Prefilled Syringe, anti IL5 receptor antibodies.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/placebo-matching-mepolizumab.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Placebo matching mepolizumab — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Placebo matching mepolizumab (Placebo matching mepolizumab) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: IL-5 inhibitor. Area: Immunology.

phase 3 IL-5 inhibitor IL-5 Immunology Small molecule Live · refreshed every 30 min

Target snapshot

Placebo matching mepolizumab (Placebo matching mepolizumab) — GlaxoSmithKline. Mepolizumab is an IL-5 inhibitor, which works by binding to the IL-5 protein and preventing it from interacting with its receptor on the surface of eosinophils, thereby reducing eosinophilic inflammation.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Placebo matching mepolizumab TARGET	Placebo matching mepolizumab	GlaxoSmithKline	phase 3	IL-5 inhibitor	IL-5
Asthma therapies	Asthma therapies	Genentech, Inc.	marketed	Monoclonal antibodies (multiple agents with different targets)	IgE, IL-5, IL-4 receptor alpha (varies by specific agent)
Fasenra®	Fasenra®	AstraZeneca	marketed	IL-5 receptor antagonist monoclonal antibody	IL-5Rα (interleukin-5 receptor alpha)
EXDENSUR	DEPEMOKIMAB-ULAA	GLAXOSMITHKLINE LLC	marketed		IL-5
Mepolizumab Injection [Nucala]	Mepolizumab Injection [Nucala]	KU Leuven	marketed	IL-5 antagonist monoclonal antibody	IL-5 (Interleukin-5)
Benralizumab Prefilled Syringe	Benralizumab Prefilled Syringe	Nantes University Hospital	marketed	IL-5 receptor antagonist monoclonal antibody	IL-5 receptor alpha (IL-5Rα)
anti IL5 receptor antibodies	anti IL5 receptor antibodies	Scarlata, Simone, M.D.	marketed	IL-5 receptor antagonist monoclonal antibody	IL-5 receptor (IL-5R)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (IL-5 inhibitor class)

AstraZeneca · 1 drug in this class
GlaxoSmithKline · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Placebo matching mepolizumab — Competitive Intelligence Brief. https://druglandscape.com/ci/placebo-matching-mepolizumab. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab